盛诺基淫羊藿素软胶囊新增治疗胰腺癌适应症获临床批件

Core Insights - Beijing Shengnuo Pharmaceutical Technology Co., Ltd. received approval for clinical trials of its product, Icariin Soft Capsule, in combination with AG regimen for treating locally advanced unresectable or metastatic pancreatic cancer [1] Group 1: Clinical Trial Approval - The National Medical Products Administration approved the clinical trial for Icariin Soft Capsule in combination with albumin-bound paclitaxel and gemcitabine for pancreatic cancer treatment [1] - Pancreatic cancer has a low 5-year survival rate of less than 10%, with most patients diagnosed at an advanced stage [1] Group 2: Research Findings - A study from Zhejiang University included 20 newly diagnosed patients with advanced pancreatic ductal adenocarcinoma (PDAC), showing an objective response rate (ORR) of 50% and a disease control rate (DCR) of 90% [1] - The 6-month survival rate was reported at 90%, with 35% of initially unresectable patients becoming resectable after treatment [1] - The results indicate significant potential for Icariin in combination chemotherapy for pancreatic cancer [1] Group 3: Collaborative Research - Shengnuo Pharmaceutical collaborated with Nankai University and Peking University Cancer Hospital to conduct in vitro experiments using organoids from pancreatic cancer patients [2] - The experiments confirmed significant synergistic effects of Icariin with first-line treatments (gemcitabine + albumin-bound paclitaxel) and (albumin-bound paclitaxel + PD-1 antibody) [2] - Icariin was observed to promote T cell migration towards tumor organoids, further validating clinical synergistic results and providing a basis for upcoming clinical trials [2]